Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
BIOS Capital Management, LP (CIK 1813845) reported $41.7M across 6 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: ACTU ($15.4M, 36.90%), IRD ($15.1M, 36.33%), CGTX ($6.9M, 16.56%), RNTX ($3.1M, 7.44%), LTRN ($1.0M, 2.50%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ACTU | ACTUATE THERAPEUTICS INC | $15.4M | 36.90% | 10.0M | Hold |
| 2 | IRD | OPUS GENETICS INC | $15.1M | 36.33% | 3.7M | Hold |
| 3 | CGTX | COGNITION THERAPEUTICS INC | $6.9M | 16.56% | 6.0M | Hold |
| 4 | RNTX | REIN THERAPEUTICS INC | $3.1M | 7.44% | 3.0M | Added |
| 5 | LTRN | LANTERN PHARMA INC | $1.0M | 2.50% | 249,397 | Trimmed |
| 6 | INAB | IN8BIO INC | $114,149 | 0.27% | 80,957 | Trimmed |
Source: SEC Form 13F filings · as of 2026-06-30